Skip to main content
Category

Advocacy

FDA Food and Drug Admin Logo
Advocacy

FDA Workshop: Opportunities to Improve Dose Optimization: Designing Trials and Applying Pharmacometrics

*May 2022* EGFR Resisters co-founder Jill Feldman participated as a panelist in this FDA Oncology Workship:  3a "Opportunities to Improve Dose Optimization: Designing Trials and Applying Pharmacometrics; and 3b "Opportunities to Improve Dose Optimization: Assessing Safety and Tolerability." Current strategies for determining the recommended dose(s) of anticancer agents for evaluation…